

Caroline Stokke

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9319699/publications.pdf>

Version: 2024-02-01

32
papers

709
citations

623734

14
h-index

552781

26
g-index

33
all docs

33
docs citations

33
times ranked

794
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluation of semi-quantitative measures of ¹⁸ F-flutemetamol PET for the clinical diagnosis of Alzheimer's disease. <i>Quantitative Imaging in Medicine and Surgery</i> , 2022, 12, 493-509.	2.0	6
2	EANM dosimetry committee recommendations for dosimetry of ¹⁷⁷ Lu-labelled somatostatin-receptor- and PSMA-targeting ligands. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1778-1809.	6.4	70
3	FDG PET/CT and Dosimetric Studies of ¹⁷⁷ Lu-Lilotomab Satetraxetan in a First-in-Human Trial for Relapsed Indolent non-Hodgkin Lymphoma "Are We Hitting the Target?". <i>Molecular Imaging and Biology</i> , 2022, 24, 807-817.	2.6	3
4	Comparison of [¹⁸ F]fluciclovine and [¹⁸ F]FDG PET/CT in Newly Diagnosed Multiple Myeloma Patients. <i>Molecular Imaging and Biology</i> , 2022, 24, 842-851.	2.6	12
5	FDG PET/CT parameters and correlations with tumor-absorbed doses in a phase 1 trial of ¹⁷⁷ Lu-lilotomab satetraxetan for treatment of relapsed non-Hodgkin lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1902-1914.	6.4	6
6	Left ventricular regional glucose metabolism in combination with septal scar extent identifies CRT responders. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2437-2446.	6.4	1
7	Myelosuppression in patients treated with ¹⁷⁷ Lutetium-lilotomab satetraxetan can be predicted with absorbed dose to the red marrow as the only variable. <i>Acta Oncologica</i> , 2021, 60, 1481-1488.	1.8	5
8	Is Amyloid Burden Measured by ¹⁸ F-Flutemetamol PET Associated with Progression in Clinical Alzheimer's Disease?. <i>Journal of Alzheimer's Disease</i> , 2021, , 1-9.	2.6	2
9	EANM dosimetry committee series on standard operational procedures: a unified methodology for ^{99m} Tc-MAA pre- and ⁹⁰ Y peri-therapy dosimetry in liver radioembolization with ⁹⁰ Y microspheres. <i>EJNMMI Physics</i> , 2021, 8, 77.	2.7	61
10	New Targets for PET Imaging of Myeloma. <i>Hemato</i> , 2021, 2, 727-738.	0.6	3
11	Regional myocardial work by cardiac magnetic resonance and non-invasive left ventricular pressure: a feasibility study in left bundle branch block. <i>European Heart Journal Cardiovascular Imaging</i> , 2020, 21, 143-153.	1.2	10
12	Phase 1/2a study of ¹⁷⁷ Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma. <i>Blood Advances</i> , 2020, 4, 4091-4101.	5.2	33
13	EANM Dosimetry Committee series on standard operational procedures for internal dosimetry for ¹³¹ I mIBG treatment of neuroendocrine tumours. <i>EJNMMI Physics</i> , 2020, 7, 15.	2.7	44
14	Amyloid- β PET "Correlation with cerebrospinal fluid biomarkers and prediction of Alzheimer's disease diagnosis in a memory clinic. <i>PLoS ONE</i> , 2019, 14, e0221365.	2.5	37
15	The Effect of New Formulas for Lean Body Mass on Lean-Body-Mass "Normalized SUV in Oncologic ¹⁸ F-FDG PET/CT. <i>Journal of Nuclear Medicine Technology</i> , 2018, 46, 253-259.	0.8	5
16	Pre-dosing with lilotomab prior to therapy with ¹⁷⁷ Lu-lilotomab satetraxetan significantly increases the ratio of tumor to red marrow absorbed dose in non-Hodgkin lymphoma patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1233-1241.	6.4	21
17	Respiratory motion during ⁹⁰ Yttrium PET contributes to underestimation of tumor dose and overestimation of normal liver tissue dose. <i>Acta Radiologica</i> , 2018, 59, 132-139.	1.1	2
18	Biodistribution and Dosimetry Results from a Phase 1 Trial of Therapy with the Antibody "Radionuclide Conjugate ¹⁷⁷ Lu-Lilotomab Satetraxetan. <i>Journal of Nuclear Medicine</i> , 2018, 59, 704-710.	5.0	16

#	ARTICLE	IF	CITATIONS
19	Combining radioiodine and external beam radiation therapy: the potential of integrated treatment planning for differentiated thyroid cancer. <i>Acta Oncologica</i> , 2017, 56, 894-897.	1.8	3
20	Tumor-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with the Anti-CD37 Antibody Radionuclide Conjugate ¹⁷⁷ Lu-Lilotomab Satetraxetan. <i>Journal of Nuclear Medicine</i> , 2017, 58, 48-54.	5.0	29
21	Red Marrow ¹⁷⁷ Lu-Lilotomab Satetraxetan, a Novel Anti-CD37 Antibody Radionuclide Conjugate. <i>Journal of Nuclear Medicine</i> , 2017, 58, 55-61.	5.0	22
22	Variations in the practice of molecular radiotherapy and implementation of dosimetry: results from a European survey. <i>EJNMMI Physics</i> , 2017, 4, 28.	2.7	65
23	Dosimetry-based treatment planning for molecular radiotherapy: a summary of the 2017 report from the Internal Dosimetry Task Force. <i>EJNMMI Physics</i> , 2017, 4, 27.	2.7	71
24	Short-course PET based simultaneous integrated boost for locally advanced cervical cancer. <i>Radiation Oncology</i> , 2016, 11, 39.	2.7	14
25	¹⁷⁷ Lu-Satetraxetan-Lilotomab in the Treatment of Patients with Indolent Non-Hodgkin B-Cell Lymphoma (NHL), Phase 1/2 Safety and Efficacy Data from Four Different Pre-Dosing Regimens. <i>Blood</i> , 2016, 128, 1780-1780.	1.4	2
26	New distinct compartments in the G ₂ phase of the cell cycle defined by the levels of γ H2AX. <i>Cell Cycle</i> , 2015, 14, 3261-3269.	2.6	7
27	Efficacy and Safety Results of a Phase 1 Study of ¹⁷⁷ Lu-DOTA-HH1 (Betalutin [®]) with and without HH1 Pre-Dosing for Patients with Relapsed CD37+ Non-Hodgkin B Cell Lymphoma (NHL). <i>Blood</i> , 2015, 126, 5118-5118.	1.4	0
28	Escherichia coli SeqA Structures Relocalize Abruptly upon Termination of Origin Sequestration during Multifork DNA Replication. <i>PLoS ONE</i> , 2014, 9, e110575.	2.5	9
29	How to measure CT image quality: Variations in CT-numbers, uniformity and low contrast resolution for a CT quality assurance phantom. <i>Physica Medica</i> , 2014, 30, 521-526.	0.7	51
30	A Phase I Study of ¹⁷⁷ Lu-DOTA-HH1 (Betalutin) Radioimmunotherapy for Patients with Relapsed CD37+ Non-Hodgkin's B Cell Lymphoma. <i>Blood</i> , 2014, 124, 3094-3094.	1.4	3
31	An Easy-To-Use Simulation Program Demonstrates Variations in Bacterial Cell Cycle Parameters Depending on Medium and Temperature. <i>PLoS ONE</i> , 2012, 7, e30981.	2.5	50
32	Replication patterns and organization of replication forks in <i>Vibrio cholerae</i> . <i>Microbiology (United Kingdom)</i> 157:46-54 (2011)	1.8	46